These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 21219199

  • 21. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB, Shepler BM.
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [Abstract] [Full Text] [Related]

  • 22. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE, Rosenbaum DP, Yang Y, Chertow GM.
    J Am Soc Nephrol; 2021 Jun 01; 32(6):1465-1473. PubMed ID: 33766811
    [Abstract] [Full Text] [Related]

  • 23. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L, Mendelssohn D, Dunn E, Hutchison C, Grima DT.
    J Med Econ; 2013 Jun 01; 16(1):1-9. PubMed ID: 22857538
    [Abstract] [Full Text] [Related]

  • 24. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.
    J Nephrol; 2001 Jun 01; 14(3):176-83. PubMed ID: 11439741
    [Abstract] [Full Text] [Related]

  • 25. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.
    Weir MA, Jain AK, Gomes T, Juurlink DN, Mamdani M, Li L, Garg AX.
    Am J Kidney Dis; 2011 Feb 01; 57(2):357-9. PubMed ID: 21251552
    [No Abstract] [Full Text] [Related]

  • 26. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 01; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 27. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP, Perianayagam MC, Jaber BL.
    J Ren Nutr; 2009 Sep 01; 19(5):432-8. PubMed ID: 19464926
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N, Lindholm B, Stenvinkel P.
    Semin Dial; 2008 Sep 01; 21(5):385-9. PubMed ID: 18573137
    [Abstract] [Full Text] [Related]

  • 30. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV, Shilov EM, Svistunov AA, Milovanov IuS.
    Ter Arkh; 2013 Sep 01; 85(6):96-9. PubMed ID: 23875200
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun 01; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 32. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM.
    Adv Ren Replace Ther; 2003 Apr 01; 10(2):133-45. PubMed ID: 12879374
    [Abstract] [Full Text] [Related]

  • 33. Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis.
    Grima DT, Dunn ES, Bernard LM, Mendelssohn DC.
    Curr Med Res Opin; 2013 Feb 01; 29(2):109-15. PubMed ID: 23216385
    [Abstract] [Full Text] [Related]

  • 34. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial.
    Akizawa T, Tsuruta Y, Okada Y, Miyauchi Y, Suda A, Kasahara H, Sasaki N, Maeda Y, Suzuki T, Matsui N, Niwayama J, Suzuki T, Hara H, Asano Y, Komemushi S, Fukagawa M.
    BMC Nephrol; 2014 Jun 25; 15():98. PubMed ID: 24968790
    [Abstract] [Full Text] [Related]

  • 35. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F.
    G Ital Nefrol; 2010 Jun 25; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [Abstract] [Full Text] [Related]

  • 36. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
    Lammoglia JJ, Mericq V.
    Horm Res; 2009 Jun 25; 71(3):178-84. PubMed ID: 19188744
    [Abstract] [Full Text] [Related]

  • 37. What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?
    Oh MS, Uribarri J.
    Clin J Am Soc Nephrol; 2014 May 25; 9(5):967-70. PubMed ID: 24408115
    [Abstract] [Full Text] [Related]

  • 38. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.
    Chow KM, Szeto CC, Kwan BC, Leung CB, Li PK.
    J Nephrol; 2007 May 25; 20(6):674-82. PubMed ID: 18046669
    [Abstract] [Full Text] [Related]

  • 39. The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
    Ketteler M.
    Int J Artif Organs; 2009 Feb 25; 32(2):95-100. PubMed ID: 19363781
    [Abstract] [Full Text] [Related]

  • 40. Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice.
    Winkelmayer WC, Tonelli M.
    Am J Kidney Dis; 2008 Mar 25; 51(3):362-5. PubMed ID: 18295050
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.